Rilmenidine (hemifumarate) (Standard)

Rilmenidine (hemifumarate) (Standard) is the analytical standard of Rilmenidine (hemifumarate) . This product is intended for research and analytical applications. Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy. Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells [1][2][3].

Product Specifications

CAS Number

[207572-68-7]

UNSPSC

12352005

Target

Adrenergic Receptor; Apoptosis; Autophagy; Imidazoline Receptor; Reference Standards

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Cancer; Cardiovascular Disease

Smiles

O=C(O)/C=C/C(O)=O.C1(NC(C2CC2)C3CC3)=NCCO1

Molecular Formula

C10H16N2O.1/2C4H4O4

Molecular Weight

238.28

References & Citations

[1]Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13 (6 Pt 2) :106S-111S.|[2]Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180.|[3]Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19 (11) :2144-2153.